ArticleNature communications2023
An ISO-certified genomics workflow for identification and surveillance of antimicrobial resistance.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
105 citing papers in PubMed, 1 synthesis or guideline pooled it, 153 citations in OpenAlex.
- Trends in horizontal gene transfer research inFrontiers in microbiology · 2024Pooled it
- Genomic investigation and clinical correlates of theAntimicrobial agents and chemotherapy · 2024Trial
- Evaluating packaged ice safety using culture-based and metagenomic methods.Microbiology (Reading, England) · 2026Article
- Antimicrobial Resistance and Associated Genetic Determinants ofAntibiotics (Basel, Switzerland) · 2026Article
- Genomic diversity, antimicrobial resistance, and virulence-associated characteristics of Escherichia coli recovered from poultry hatchery-box material.Poultry science · 2026Article
- Antibiotic-Specific Genotype-Phenotype Concordance and Cross-Database Interoperability in PublicInternational journal of molecular sciences · 2026Article
- Clinical Emergence and Genomic Characterization of Aztreonam-Avibactam-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Article
- Long-term trends in ceftolozane-tazobactam susceptibility among gram-negative pathogens in the United States: a nine-year SMART analysis (2016-2024).JAC-antimicrobial resistance · 2026Article
- Comprehensive Phenotypic Characterization of ClinicalInternational journal of molecular sciences · 2026Article
- Genetic and pharmacological inactivation of peptidoglycan remodeling increases antibiotic susceptibility of vancomycin-resistant Enterococcus faecium.Nature communications · 2026Article
- Nationwide spread of multidrug resistant Klebsiella pneumoniae across US communities.Nature communications · 2026Article
- The need to strengthen laboratory leadership, systems, and networks to enhance outbreak detection and resilience in Africa: proceedings of a regional workshop.BMC proceedings · 2026Article
- Genomic surveillance of post-immunization pneumococcal carriage in Ghana.Microbial genomics · 2026Article
- A WGS workflow for identifying genetically modified and foodborne-pathogenicFood chemistry. Molecular sciences · 2026Article
- Genomic analysis of Vibrio cholerae in Western Kenya (2015-2023) reveals persistence of pandemic ST69 and presence of the European-associated ST8 lineage.BMC genomics · 2026Article
- Review
- Antimicrobial Resistance in Veterinary Bacterial Pathogens: Resistance Patterns, Zoonotic Risks and One Health Implications.Pathogens (Basel, Switzerland) · 2026Review
- Towards accurate genomic detection of fungal antimicrobial resistance: progress in fungal resistance databases and bioinformatic tools.Microbial genomics · 2026Review
- Antibiotic Resistance Detection and Concomitant Species Identification of ESKAPE Pathogens by Proteomics.Molecular & cellular proteomics : MCP · 2026Article
45 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Realising the promise of genomics to revolutionise identification and surveillance of antimicrobial resistance (AMR) has been a long-standing challenge in clinical and public health microbiology. Here, we report the creation and validation of abritAMR, an ISO-certified bioinformatics platform for genomics-based bacterial AMR gene detection. The abritAMR platform utilises NCBI's AMRFinderPlus, as well as additional features that classify AMR determinants into antibiotic classes and provide customised reports. We validate abritAMR by comparing with PCR or reference genomes, representing 1500 different bacteria and 415 resistance alleles. In these analyses, abritAMR displays 99.9% accuracy, 97.9% sensitivity and 100% specificity. We also compared genomic predictions of phenotype for 864 Salmonella spp. against agar dilution results, showing 98.9% accuracy. The implementation of abritAMR in our institution has resulted in streamlined bioinformatics and reporting pathways, and has been readily updated and re-verified. The abritAMR tool and validation datasets are publicly available to assist laboratories everywhere harness the power of AMR genomics in professional practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.